Antibiotice Ia (ATB) - Total Assets
Based on the latest financial reports, Antibiotice Ia (ATB) holds total assets worth RON1.39 Billion RON (≈ $319.75 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Antibiotice Ia (ATB) shareholders funds for net asset value and shareholders' equity analysis.
Antibiotice Ia - Total Assets Trend (2020–2025)
This chart illustrates how Antibiotice Ia's total assets have evolved over time, based on quarterly financial data.
Antibiotice Ia - Asset Composition Analysis
Current Asset Composition (September 2025)
Antibiotice Ia's total assets of RON1.39 Billion consist of 36.3% current assets and 63.7% non-current assets.
| Asset Category | Amount (RON) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 0.7% |
| Accounts Receivable | RON339.09 Million | 24.4% |
| Inventory | RON182.34 Million | 13.1% |
| Property, Plant & Equipment | RON0.00 | 0.0% |
| Intangible Assets | RON69.95 Million | 5.0% |
| Goodwill | RON0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Antibiotice Ia's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ATB company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Antibiotice Ia's current assets represent 36.3% of total assets in 2025, a decrease from 43.5% in 2020.
- Cash Position: Cash and equivalents constituted 0.7% of total assets in 2025, down from 0.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 24.4% of total assets.
Antibiotice Ia Competitors by Total Assets
Key competitors of Antibiotice Ia based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ipsen SA
PA:IPN
|
France | €6.83 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs25.34 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥16.53 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915
|
China | CN¥4.78 Billion |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
China | CN¥2.39 Billion |
Antibiotice Ia - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.02 | 2.16 |
| Quick Ratio | 1.29 | 1.30 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RON255.33 Million | RON239.64 Million | RON201.72 Million |
Antibiotice Ia - Advanced Valuation Insights
This section examines the relationship between Antibiotice Ia's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | RON1.39 Billion |
| Market Capitalization | $332.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Antibiotice Ia's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Antibiotice Ia's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Antibiotice Ia (2020–2025)
The table below shows the annual total assets of Antibiotice Ia from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | RON1.39 Billion ≈ $319.75 Million |
+8.86% |
| 2024-09-30 | RON1.28 Billion ≈ $293.74 Million |
+12.30% |
| 2023-09-30 | RON1.14 Billion ≈ $261.57 Million |
+33.01% |
| 2022-09-30 | RON856.47 Million ≈ $196.66 Million |
-4.35% |
| 2021-09-30 | RON895.39 Million ≈ $205.60 Million |
+3.75% |
| 2020-09-30 | RON863.00 Million ≈ $198.16 Million |
-- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more